Miraculins Inc.

Miraculins Inc.

April 24, 2007 09:03 ET

Miraculins to Present at BioFinance 2007 in Toronto

WINNIPEG, MANITOBA--(CCNMatthews - April 24, 2007) - Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company engaged in the discovery and development of biomarkers and diagnostics for select cancers, is pleased to announce that the Company will be providing a corporate update at BioFinance 2007 in Toronto.

Christopher J. Moreau, Miraculins President and CEO will give his corporate presentation of the Company on Wednesday, April 25 in the Trinity V room of the Toronto Marriot Eaton Centre. Mr. Moreau is scheduled to present at 10:30 am Eastern Time.

"BioFinance is a very well organized and well run life sciences conference and I was very pleased that Miraculins was invited back to present again this year", stated Mr. Moreau.

BioFinance 2007 is the Canadian forum for some of the most innovative minds in the life sciences industry today. The BioFinance forum attracts leading corporate investors and venture capital from Canada, the United States and Europe.

About Miraculins Inc.

Miraculins is discovering, validating and developing biological markers (biomarkers) with clinical relevance for the diagnosis and treatment of cancers with critical unmet needs. The importance of tumor biomarkers for "common" cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society. The Company's B.E.S.T. Platform™ utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information